跳至主要内容
临床试验/NCT01713686
NCT01713686已完成不适用

Prospective, Multi-center, Pivotal Trial Evaluating the Safety and Effectiveness of the Ulthera® System for Improvement in Lines and Wrinkles of the Décolletage

Ulthera, Inc8 个研究点 分布在 1 个国家目标入组 129 人开始时间: 2012年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Ulthera, Inc
入组人数
129
试验地点
8
主要终点
Percentage of Participants With a Reduction in Chest Wrinkles at 90 Days Post Treatment

研究概览

简要总结

This is prospective, multi-center clinical trial. Enrolled subjects will receive one Ulthera® treatment on the decolletage. Follow-up visits will occur at 90 and 180 days following treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
35 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Female, aged 35 to 70 years.
  • Subject in good health.
  • Moderate to severe skin lines and wrinkles on the décolletage; grade of ≥4 on a chest wrinkle scale.
  • Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.
  • Willingness and ability to comply with protocol requirements.
  • Subjects of childbearing potential must have a negative urine pregnancy test result and must not be lactating.
  • Absence of physical conditions unacceptable to the investigator.
  • Willingness and ability to provide written consent for study-required photography.
  • Willingness and ability to provide written informed consent.

排除标准

  • Presence of an active systemic or local skin disease that may affect wound healing.
  • Scarring in areas to be treated.
  • Tattoos in the areas to be treated.
  • Patients with ports or defibrillators.
  • Any open wounds or lesions in the area.
  • Active and severe inflammatory acne in the region to be treated.
  • Patients who have a history with keloid formation or hypertrophic scarring.
  • Inability to understand the protocol or to give informed consent.
  • Retinoid, microdermabrasion, or prescription level glycolic acid treatments to the décolletage area within two weeks prior to study participation or during the study.
  • Marked décolletage asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin.
  • History of chronic drug or alcohol abuse.
  • History of autoimmune disease.
  • Concurrent therapy that would interfere with the evaluation of the safety or effectiveness of the study device.
  • Subjects who anticipate the need for surgery or overnight hospitalization during the study.
  • Subjects who have a history of poor cooperation, noncompliance with medical treatment, or unreliability.
  • Concurrent enrollment in any study involving the use of investigational devices or drugs.
  • Current smoker or history of smoking in the last one year.
  • History of using the following prescription medications:
  • Topical Retinoids to the area within the past two weeks;
  • Antiplatelet agents/anticoagulants (Coumadin, Heparin, Plavix).
  • Psychiatric drugs that would impair the subject from understanding the protocol requirements or understanding and signing the informed consent.

结局指标

主要结局

Percentage of Participants With a Reduction in Chest Wrinkles at 90 Days Post Treatment

时间窗: 90 Days post-treatment

Assessment of improvement, in a blinded fashion, using a Chest Wrinkle Scale at 90 days post-treatment. However, during conduct of the trial, the Chest Wrinkle scale was deemed inadequate as a primary endpoint in this study. Therefore, conduct of a traditional blinded masked assessment, the gold-standard measure in aesthetics, was used as the primary endpoint,i.e., improvement in wrinkles and lines of the décolletage as determined by a blinded, masked, qualitative assessment of photographs at 90 days post-treatment compared to baseline. "Improvement" = a blinded evaluator assessed an "Improvement" when evaluating a masked, paired photo set and correctly chose the Post treatment photo. "Incorrect" = a blinded evaluator assessed an "Improvement" when evaluating a masked, paired photo set but incorrectly chose the Post treatment photo.

Percentage of Participants With a Reduction in Chest Wrinkles at 180 Days Post Treatment

时间窗: 180 days post treatment

Assessment of improvement, in a blinded fashion, using a Chest Wrinkle Scale at 180 days post-treatment. However, during conduct of the trial, the Chest Wrinkle scale was deemed inadequate as a primary endpoint in this study. Therefore, conduct of a traditional blinded masked assessment, the gold-standard measure in aesthetics, was used as the primary endpoint, improvement in wrinkles and lines of the décolletage as determined by a blinded, masked, qualitative assessment of photographs at 180 days .post-treatment compared to baseline. "Improvement" = a blinded evaluator assessed an "Improvement" when evaluating a masked, paired photo set and correctly chose the Post treatment photo. "Incorrect" = a blinded evaluator assessed an "Improvement" when evaluating a masked, paired photo set but incorrectly chose the Post treatment photo.

次要结局

  • Overall Aesthetic Improvement at 180 Days Post-treatment(180 days post-treatment)
  • Subject Satisfaction at 180 Days Post-treatment(180 days post-treatment)
  • Subject Satisfaction at 90 Days Post-treatment(90 days post-treatment)
  • Overall Aesthetic Improvement at 90 Days Post-treatment(90 days post-treatment)

研究者

发起方
Ulthera, Inc
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验

Evaluation of the Ulthera System for the Treatment... | 临床试验